▁Bre 8.0234375
ast 1.962890625
▁cancer 1.630859375
▁is 1.189453125
▁a 1.736328125
▁complex 3.80078125
▁and 2.330078125
▁potentially 4.19921875
▁life 1.95703125
- 0.137451171875
th 0.053863525390625
re 1.4662742614746094e-05
aten 0.0030727386474609375
ing 0.0016002655029296875
▁disease 0.2412109375
▁that 1.6572265625
▁affect 1.3359375
s 0.0011157989501953125
▁both 3.1015625
▁women 1.2880859375
▁and 0.00763702392578125
▁men 0.01491546630859375
. 0.25341796875
▁Vari 8.1953125
ous 0.0333251953125
▁critical 9.7421875
▁factors 1.0322265625
▁contribute 2.546875
▁to 0.019317626953125
▁its 2.1875
▁development 0.66357421875
, 0.62646484375
▁including 0.58544921875
▁her 3.74609375
ed 0.325439453125
ity 0.00046634674072265625
, 0.25634765625
▁dise 10.53125
ases 0.04443359375
▁of 2.33203125
▁the 0.1259765625
▁m 3.814453125
amm 0.0142364501953125
ary 0.0021610260009765625
▁g 0.0266265869140625
lands 0.326171875
, 0.1724853515625
▁and 1.5322265625
▁h 2.384765625
orm 0.0008955001831054688
onal 0.30712890625
▁factors 2.12109375
. 0.1463623046875
▁Det 6.57421875
ect 0.583984375
ing 0.015625
▁early 3.736328125
▁met 7.671875
ast 0.034576416015625
asis 1.216796875
▁and 2.03125
▁determ 3.939453125
ining 0.003894805908203125
▁the 0.4111328125
▁ag 3.939453125
gress 0.01398468017578125
iveness 0.065673828125
▁of 0.059600830078125
▁the 0.54931640625
▁cancer 2.5625
▁type 5.046875
▁are 1.0439453125
▁cru 1.9248046875
cial 0.007076263427734375
▁for 0.97900390625
▁successful 1.5595703125
▁treatment 0.3203125
▁and 1.6220703125
▁improved 4.24609375
▁patient 1.54296875
▁out 0.74609375
comes 0.0096588134765625
. 0.0274658203125
<0x0A> 0.73583984375
First 8.4765625
ly 2.09375
, 0.004917144775390625
▁her 6.84765625
ed 0.340087890625
ity 0.0007901191711425781
▁plays 1.4951171875
▁a 0.141357421875
▁significant 0.57958984375
▁role 0.00827789306640625
▁in 0.053436279296875
▁breast 1.228515625
▁cancer 0.004627227783203125
▁development 0.5849609375
. 0.4150390625
▁C 3.658203125
ertain 0.01386260986328125
▁gen 0.33935546875
etic 0.39501953125
▁mut 0.293701171875
ations 0.0005731582641601562
, 1.0830078125
▁such 0.22021484375
▁as 0.00026679039001464844
▁BR 0.346923828125
CA 0.0007486343383789062
1 0.09942626953125
▁and 0.1571044921875
▁BR 0.0177459716796875
CA 0.0004100799560546875
2 0.00274658203125
, 0.0789794921875
▁can 1.21875
▁be 6.07421875
▁inherited 1.0654296875
▁from 0.6015625
▁parents 0.62109375
▁and 0.289794921875
▁increase 0.29931640625
▁the 0.1524658203125
▁risk 0.045684814453125
▁of 0.007965087890625
▁developing 0.267578125
▁breast 0.4501953125
▁cancer 0.036224365234375
. 0.1754150390625
▁Ind 4.3046875
ividual 0.0016498565673828125
s 0.0030002593994140625
▁with 0.1641845703125
▁a 0.34228515625
▁family 0.1435546875
▁history 0.001255035400390625
▁of 0.01139068603515625
▁breast 0.11187744140625
▁or 2.603515625
▁o 0.07330322265625
var 0.00012004375457763672
ian 2.6702880859375e-05
▁cancer 0.023834228515625
▁need 7.45703125
▁to 0.1875
▁be 0.493896484375
▁more 2.171875
▁vig 0.55810546875
il 1.1920928955078125e-05
ant 0.0001220703125
▁about 0.85009765625
▁regular 1.8349609375
▁screen 0.76708984375
ings 1.1259765625
▁and 0.26025390625
▁may 3.140625
▁consider 1.5986328125
▁gen 0.458740234375
etic 0.000148773193359375
▁testing 0.08062744140625
▁to 0.325927734375
▁assess 1.4296875
▁their 0.0712890625
▁risk 0.06964111328125
. 0.3876953125
<0x0A> 0.129150390625
Second 0.5888671875
ly 0.007465362548828125
, 0.00024306774139404297
▁dise 0.7685546875
ases 0.0005617141723632812
▁of 0.06402587890625
▁the 0.001308441162109375
▁m 0.0230712890625
amm 8.07046890258789e-05
ary 0.0006728172302246094
▁g 0.0011997222900390625
lands 0.032135009765625
▁can 1.4169921875
▁contribute 2.16796875
▁to 0.002105712890625
▁the 0.79638671875
▁development 0.0504150390625
▁of 0.00493621826171875
▁breast 0.0165252685546875
▁cancer 0.0005826950073242188
. 0.057464599609375
▁Cond 2.859375
itions 2.5272369384765625e-05
▁such 0.10113525390625
▁as 4.9233436584472656e-05
▁at 3.966796875
yp 0.06365966796875
ical 0.01229095458984375
▁hyper 0.2103271484375
pl 0.00013577938079833984
asia 0.00441741943359375
▁and 0.890625
▁lo 1.103515625
b 0.0012197494506835938
ular 0.002117156982421875
▁car 0.01934814453125
cin 2.4437904357910156e-05
oma 0.0005445480346679688
▁in 0.045166015625
▁situ 0.002712249755859375
▁can 1.4736328125
▁increase 0.2130126953125
▁the 0.0248260498046875
▁lik 4.703125
elihood 9.274482727050781e-05
▁of 0.001285552978515625
▁developing 0.384765625
▁invas 2.634765625
ive 6.198883056640625e-06
▁breast 0.58154296875
▁cancer 0.0013151168823242188
. 0.56982421875
▁Additionally 3.861328125
, 0.00012791156768798828
▁individuals 3.865234375
▁who 1.6953125
▁have 0.2022705078125
▁previously 3.224609375
▁had 1.72265625
▁breast 0.30810546875
▁cancer 0.0645751953125
▁or 1.7041015625
▁ben 2.869140625
ign 1.3113021850585938e-06
▁breast 0.1768798828125
▁dise 1.7958984375
ases 2.872943878173828e-05
▁like 4.0859375
▁fib 0.31689453125
roc 0.69091796875
yst 9.465217590332031e-05
ic 0.0004177093505859375
▁changes 0.66064453125
▁need 4.92578125
▁to 0.027496337890625
▁be 0.1456298828125
▁monitor 2.79296875
ed 0.000240325927734375
▁more 1.6787109375
▁closely 0.0283050537109375
▁to 2.24609375
▁detect 0.389404296875
▁any 0.318359375
▁potential 2.603515625
▁rec 0.470947265625
urrence 0.5
▁or 1.078125
▁new 0.424072265625
▁m 2.380859375
align 0.00510406494140625
an 0.495361328125
cies 2.384185791015625e-06
. 0.028289794921875
<0x0A> 0.01073455810546875
H 1.72265625
orm 0.0008492469787597656
onal 0.06207275390625
▁factors 0.0112152099609375
▁also 1.150390625
▁play 0.1114501953125
▁a 0.05889892578125
▁role 0.7373046875
▁in 0.007640838623046875
▁breast 0.294921875
▁cancer 0.0003235340118408203
. 4.0390625
▁Est 0.5439453125
ro 0.00801849365234375
gen 3.0159950256347656e-05
▁and 0.27490234375
▁pro 0.004642486572265625
g 0.0052642822265625
ester 2.384185791015625e-06
one 0.00016510486602783203
, 1.6845703125
▁female 3.8125
▁sex 0.46533203125
▁h 0.007610321044921875
orm 1.1920928955078125e-07
ones 0.0007381439208984375
, 0.1602783203125
▁can 0.31201171875
▁stim 0.89404296875
ulate 3.7670135498046875e-05
▁the 0.11578369140625
▁growth 0.0721435546875
▁of 0.085205078125
▁certain 2.9765625
▁breast 0.62646484375
▁cancer 0.43017578125
▁cells 0.176025390625
. 0.339111328125
▁Women 1.78125
▁who 0.48828125
▁start 4.93359375
▁men 0.322021484375
stru 0.3544921875
ating 0.1422119140625
▁early 0.83544921875
, 0.560546875
▁experience 2.8671875
▁late 2.638671875
▁men 0.024993896484375
op 0.0004563331604003906
ause 0.0005764961242675781
, 0.03387451171875
▁or 0.446044921875
▁have 0.459228515625
▁never 2.34375
▁been 0.87890625
▁pre 0.002712249755859375
gn 2.0623207092285156e-05
ant 8.952617645263672e-05
▁are 0.787109375
▁at 0.44189453125
▁a 0.8349609375
▁higher 0.0433349609375
▁risk 0.00010418891906738281
▁of 0.07110595703125
▁developing 0.01849365234375
▁breast 0.074951171875
▁cancer 0.0002027750015258789
▁due 2.080078125
▁to 0.0002110004425048828
▁prolong 2.236328125
ed 0.00022554397583007812
▁expos 0.1158447265625
ure 3.9458274841308594e-05
▁to 0.004138946533203125
▁these 0.431640625
▁h 0.0009908676147460938
orm -0.0
ones 0.004322052001953125
. 0.01403045654296875
▁H 3.521484375
orm 0.00360870361328125
one 0.268310546875
▁replacement 0.372802734375
▁ther 0.00012862682342529297
apy 0.0032806396484375
▁after 3.25390625
▁men 0.0012464523315429688
op 8.344650268554688e-06
ause 0.00032019615173339844
▁can 0.470458984375
▁also 0.1043701171875
▁increase 0.025848388671875
▁the 0.08892822265625
▁risk 0.006626129150390625
, 3.689453125
▁and 1.99609375
▁therefore 5.87109375
, 0.422119140625
▁careful 5.87890625
▁consideration 0.5859375
▁should 1.111328125
▁be 0.0012311935424804688
▁given 0.16650390625
▁to 0.37744140625
▁its 1.6435546875
▁use 0.05126953125
. 0.154296875
<0x0A> 0.064697265625
Det 4.38671875
ect 0.0419921875
ing 0.0007991790771484375
▁early 0.3095703125
▁met 0.11541748046875
ast 6.866455078125e-05
asis 0.00446319580078125
▁is 1.5126953125
▁cru 0.50927734375
cial 7.927417755126953e-05
▁as 4.609375
▁it 0.185791015625
▁greatly 6.4296875
▁impact 1.9033203125
s 0.0006356239318847656
▁treatment 1.8857421875
▁out 1.1416015625
comes 0.0001188516616821289
. 0.333251953125
▁Met 2.833984375
ast 0.0006570816040039062
asis 0.154296875
▁refers 1.7744140625
▁to 6.99758529663086e-05
▁the 0.06048583984375
▁spread 0.0265655517578125
▁of 0.019256591796875
▁cancer 0.03509521484375
▁cells 0.479248046875
▁from 0.61328125
▁the 0.32666015625
▁primary 0.6416015625
▁tum 1.0244140625
or 0.025543212890625
▁to 0.7705078125
▁other 0.0655517578125
▁parts 0.2476806640625
▁of 7.390975952148438e-05
▁the 2.7418136596679688e-05
▁body 2.5987625122070312e-05
. 0.83056640625
▁Early 0.642578125
▁detection 0.1934814453125
▁of 0.8212890625
▁met 0.092041015625
ast 3.731250762939453e-05
asis 0.035736083984375
▁allows 1.4970703125
▁medical 6.01953125
▁profession 0.09661865234375
als 5.0067901611328125e-06
▁to 0.00168609619140625
▁interven 0.9130859375
e 4.291534423828125e-06
▁prompt 3.34375
ly 7.033348083496094e-06
▁and 0.71533203125
▁implement 4.43359375
▁appropriate 2.109375
▁treatment 0.36328125
▁strateg 1.40625
ies 1.430511474609375e-06
. 0.87939453125
▁Method 8.109375
s 0.0032138824462890625
▁used 2.158203125
▁to 0.3984375
▁determine 5.765625
▁met 0.81005859375
ast 8.499622344970703e-05
asis 0.024932861328125
▁include 0.1851806640625
▁imag 0.8642578125
ing 0.00011861324310302734
▁techniques 1.5751953125
▁like 1.7314453125
▁CT 2.5625
▁sc 0.2294921875
ans 0.001522064208984375
, 0.4453125
▁P 2.41015625
ET 0.00028395652770996094
▁sc 0.05560302734375
ans 0.0001373291015625
, 0.0152130126953125
▁and 0.1427001953125
▁b 1.7080078125
one 0.00040531158447265625
▁sc 0.037078857421875
ans 0.005718231201171875
, 0.434814453125
▁which 1.494140625
▁can 0.442626953125
▁identify 2.263671875
▁the 1.423828125
▁presence 0.0977783203125
▁of 0.03826904296875
▁cancer 0.47021484375
▁in 1.078125
▁distant 1.333984375
▁org 0.11785888671875
ans 3.5762786865234375e-07
. 0.48974609375
<0x0A> 0.85498046875
Det 2.7265625
erm 0.01029205322265625
ining 0.0026397705078125
▁the 0.02911376953125
▁ag 0.01061248779296875
gress 0.0002853870391845703
iveness 0.0070343017578125
▁of 0.00605010986328125
▁breast 1.6962890625
▁cancer 0.0007638931274414062
▁is 0.4970703125
▁essential 2.232421875
▁for 0.7646484375
▁determ 3.322265625
ining 0.00012421607971191406
▁optimal 5.9765625
▁treatment 0.0191497802734375
▁plans 2.6171875
. 0.1107177734375
▁Vari 4.10546875
ous 0.0024242401123046875
▁factors 0.277587890625
, 0.8447265625
▁such 0.422607421875
▁as 5.137920379638672e-05
▁tum 0.96337890625
or 0.004375457763671875
▁size 0.0882568359375
, 0.08935546875
▁grade 2.04296875
, 0.299560546875
▁and 0.1859130859375
▁h 1.2470703125
orm 0.00024116039276123047
one 0.043121337890625
▁re 0.017120361328125
ceptor 0.07318115234375
▁status 0.0323486328125
, 0.032073974609375
▁help 3.78125
▁assess 3.533203125
▁the 0.11761474609375
▁ag 0.64892578125
gress 0.0020771026611328125
iveness 0.00372314453125
▁of 0.05096435546875
▁the 0.46533203125
▁cancer 0.197021484375
▁type 1.5263671875
. 0.1597900390625
▁Additionally 4.703125
, 6.175041198730469e-05
▁gen 2.138671875
etic 0.00664520263671875
▁profil 3.875
ing 8.654594421386719e-05
▁can 0.9501953125
▁provide 1.326171875
▁information 2.14453125
▁about 0.441650390625
▁specific 2.20703125
▁gene 2.5078125
▁mut 0.10528564453125
ations 0.00047087669372558594
▁that 0.29248046875
▁may 0.427734375
▁influence 2.1484375
▁the 0.66455078125
▁behavior 2.087890625
▁of 0.127197265625
▁the 0.174072265625
▁cancer 0.31005859375
▁cells 0.6474609375
. 0.2008056640625
▁This 2.52734375
▁information 0.27001953125
▁allows 3.458984375
▁health 2.783203125
care 0.0226287841796875
▁prov 0.5732421875
iders 2.0265579223632812e-06
▁to 0.002521514892578125
▁tail 1.505859375
or 0.0002918243408203125
▁treatment 0.294677734375
▁options 3.31640625
▁to 0.6328125
▁individual 2.8671875
▁patients 0.56298828125
, 1.2958984375
▁maxim 2.517578125
izing 0.0093536376953125
▁their 1.1279296875
▁ch 0.1495361328125
ances 8.940696716308594e-06
▁of 0.037689208984375
▁successful 1.2646484375
▁out 0.71142578125
comes 1.5497207641601562e-05
. 0.03729248046875
<0x0A> 0.04718017578125
In 0.97900390625
▁conclusion 0.2020263671875
, 0.00024235248565673828
▁understanding 3.0859375
▁the 0.214599609375
▁critical 1.8017578125
▁factors 0.038482666015625
▁that 0.34033203125
▁contribute 0.073974609375
▁to 0.00023376941680908203
▁breast 0.431640625
▁cancer 0.0001373291015625
▁development 0.0693359375
, 1.857421875
▁including 1.189453125
▁her 0.0328369140625
ed 0.00860595703125
ity 4.172325134277344e-06
, 0.0015897750854492188
▁dise 0.286376953125
ases 0.0002682209014892578
▁of 0.002468109130859375
▁the 0.005237579345703125
▁m 0.0014019012451171875
amm 0.00015532970428466797
ary 7.200241088867188e-05
▁g 0.00020647048950195312
lands 0.005161285400390625
, 0.004138946533203125
▁and 0.1102294921875
▁h 0.0011138916015625
orm 5.960464477539062e-07
onal 0.00797271728515625
▁factors 0.0031795501708984375
, 0.045562744140625
▁is 0.260986328125
▁vital 2.873046875
▁for 0.2095947265625
▁effective 2.021484375
▁prevent 1.6337890625
ion 0.0218353271484375
▁and 0.368896484375
▁early 2.1171875
▁detection 0.08270263671875
. 0.374267578125
▁Early 2.490234375
▁identification 4.05078125
▁of 0.10186767578125
▁met 0.0216522216796875
ast 5.352497100830078e-05
asis 0.01294708251953125
▁and 0.08721923828125
▁determ 0.270263671875
ining 0.8349609375
▁the 0.0250091552734375
▁ag 0.0046539306640625
gress 0.0001239776611328125
iveness 0.0013818740844726562
▁of 0.0005316734313964844
▁the 0.4873046875
▁cancer 0.0234222412109375
▁type 0.01824951171875
▁through 5.02734375
▁various 1.1640625
▁methods 1.2177734375
▁enable 4.32421875
▁health 1.0771484375
care 0.003360748291015625
▁profession 1.6279296875
als 1.7881393432617188e-06
▁to 0.001583099365234375
▁provide 1.748046875
▁appropriate 1.779296875
▁treatment 0.1829833984375
▁strateg 1.8828125
ies 2.0265579223632812e-06
, 1.4130859375
▁thus 4.609375
▁impro 0.2685546875
ving 9.298324584960938e-06
▁patient 0.09521484375
▁pro 5.7421875
gn 7.855892181396484e-05
osis 0.179443359375
▁and 1.205078125
▁quality 1.2294921875
▁of 0.0003867149353027344
▁life 0.0004086494445800781
. 0.00787353515625
